8-K: FutureTech II Acquisition Corp. and Longevity Biomedical, Inc. Announce Merger Agreement

FutureTech II Acquisition Corp. and Longevity Biomedical, Inc. have agreed to a business combination, with Longevity becoming a publicly traded company on the Nasdaq.

Summary

• FutureTech II Acquisition Corp., a SPAC, and Longevity Biomedical, Inc., a biopharmaceutical company, have entered into a merger agreement.
• Longevity Biomedical will become a wholly-owned subsidiary of FutureTech, which will then change its name to Longevity Biomedical, Inc.
• The combined company is expected to list on the Nasdaq Capital Market under the ticker symbol LBIO.
• The merger consideration will be $100 million, minus the value of converted stock options, divided by $10.00 per share.
• The transaction is expected to close in the fourth quarter of 2024, pending stockholder approvals and other closing conditions.
• Longevity is focused on developing and acquiring new technologies spanning therapeutics, health monitoring and digital health solutions.
• Longevity has a diversified pipeline of therapeutic candidates across ophthalmology, cardiovascular disease and soft tissue reconstruction and repair.
• The merger is also contingent on Longevity completing its acquisitions of Cerevast Medical, Inc. and Aegeria Soft Tissue, LLC.

Sentiment

Score: 8

Explanation: The document is generally positive, highlighting the potential of the merger and Longevity's pipeline. The language is optimistic and forward-looking, suggesting a positive outlook for the combined company.

Positives

• Longevity Biomedical will gain access to public markets and capital to advance its pipeline.
• The combined company will have a diversified portfolio of therapeutic candidates.
• Longevity has a seasoned management team with a track record of acquiring, developing, and commercializing novel technologies.
• The merger will allow Longevity to expand its impact in the healthcare industry.

Negatives

• The transaction is subject to stockholder approvals and other closing conditions.
• The merger is contingent on Longevity completing its acquisitions of Cerevast Medical, Inc. and Aegeria Soft Tissue, LLC.
• The value of the merger consideration is subject to adjustment based on the value of converted stock options.

Risks

• The inability to obtain required stockholder or regulatory approvals could delay or prevent the merger.
• Failure to realize the anticipated benefits of the business combination is a risk.
• There are risks relating to the uncertainty of the projected financial information with respect to the Company and Longevity.
• Longevity's ability to successfully and timely acquire, develop, sell and expand its technology and products is a risk.
• The amount of redemption requests made by FutureTech's shareholders could impact the available capital.
• The combined company may experience difficulties managing its growth and expanding operations.

Future Outlook

The combined company is expected to list on Nasdaq under the ticker symbol LBIO and will focus on advancing new technologies to promote human health and longevity. The Business Combination is expected to close in the fourth quarter of 2024.

Management Comments

• Bradford A. Zakes, Chief Executive Officer of Longevity Biomedical, stated that the business combination will provide the platform to advance cutting-edge technologies spanning multiple areas of unmet medical need for the aging population.
• Ray Chen, Chief Executive Officer of FutureTech, stated that FutureTech is excited to partner with Longevity's experienced leadership team to accelerate its clinical development pipeline.

Industry Context

This announcement reflects a trend of SPAC mergers with biotech and healthcare companies seeking to access public markets. The focus on longevity and age-related diseases aligns with growing investor interest in these areas.

Comparison to Industry Standards

• The merger structure is typical for SPAC transactions, involving a reverse merger and a change of ticker symbol.
• The focus on a diversified pipeline of therapeutic candidates is common among biopharmaceutical companies.
• The emphasis on late-stage clinical assets is intended to reduce risk and accelerate time to market.
• The use of a PIPE (private investment in public equity) is a common mechanism to raise additional capital in SPAC transactions.
• Comparable companies in the biopharmaceutical space often have similar clinical development timelines and regulatory hurdles.

Management Changes

Stakeholder Impact

• Shareholders of FutureTech will have the opportunity to vote on the merger and potentially benefit from the combined company's growth.
• Shareholders of Longevity will gain access to public markets and capital.
• Employees of both companies will be part of the new combined entity.
• Customers and partners of Longevity will benefit from the company's enhanced resources and capabilities.
• The merger will create a new publicly traded company focused on addressing unmet medical needs for the aging population.

Next Steps

• FutureTech will file a registration statement on Form S-4 with the SEC.
• FutureTech will mail a definitive proxy statement/prospectus to its stockholders.
• FutureTech and Longevity will seek stockholder approvals for the merger.
• The combined company will seek to list on Nasdaq under the ticker symbol LBIO.
• Longevity will continue to advance its clinical development pipeline.

Key Dates

Keywords

merger, acquisition, biopharmaceutical, SPAC, Nasdaq, longevity, therapeutics, health monitoring, digital health, clinical trials